Full Press Release Details
Powered and protected by
Privacy
ENTA Positive Sentiment Score: 70/100
Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
Key Takeaway: Enanta Pharmaceuticals' partner, AbbVie, has received approval from the European Commission for MAVIRET® (glecaprevir/pibrentasvir) to treat individuals with acute Hepatitis C virus. This approval is significant as it expands the treatment options available for patients suffering from this condition. The approval highlights the ongoing efforts to combat Hepatitis C effectively.
Market Sentiment Analysis
POSITIVE FACTORS
- AbbVie received European Commission approval for MAVIRET®.
- MAVIRET® is indicated for treating acute Hepatitis C.
- This approval expands treatment options for patients.
Frequently Asked Questions
What is MAVIRET® used for?
MAVIRET® is used to treat individuals with acute Hepatitis C virus.
Who received the approval for MAVIRET®?
AbbVie received the European Commission approval for MAVIRET®.
What does the approval of MAVIRET® signify?
The approval signifies an expansion of treatment options for Hepatitis C patients.